^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Ewing Sarcoma |
| Regimen: | VC (carboplatin + etoposide IV) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Excerpt:
Summary of recommendations...Ewing Sarcoma...ChT regimens in relapse situations are not standardised and include alkylating agents (cyclophosphamide and high-dose ifosfamide) in combination with topoisomerase inhibitors (etoposide and topotecan), irinotecan with temozolomide [III, B] or gemcitabine and docetaxel, or high-dose ifosfamide or carboplatin with etoposide.
DOI:
10.1093/annonc/mdy310
